Clinical outcomes after switching from omalizumab to anti-IL-5/IL-5R biologics in severe asthma: a retrospective cohort study
In severe asthma patients who do not achieve adequate control with omalizumab, switching to interleukin-5 (IL-5) targeted biological therapies may provide clinically significant improvements. Baseline clinical parameters can serve as useful predictors for the need to change biological treatment.
Authors
- Tuğba Önalan (ORCID: https://orcid.org/0000-0003-2427-5925)
- Şevket Arslan (ORCID: https://orcid.org/0000-0002-0343-0159)
- Fatma Arzu Akkuş (ORCID: https://orcid.org/0000-0003-0519-7132)
- Fatih Çölkesen (ORCID: https://orcid.org/0000-0002-6595-1267)
- Mehmet Kılınç (ORCID: https://orcid.org/0000-0003-1117-6872)
- Mehmet Emin Gerek (ORCID: https://orcid.org/0000-0003-4792-0544)
Institutions
- Batman University (TR)
- Necmettin Erbakan University (TR)
- Konya Eğitim ve Araştırma Hastanesi (TR)
Publication Details
- Journal
- BMC Pulmonary Medicine
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1186/s12890-025-04044-7
- Citations
- 1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.16